GreenLight Biosciences

GreenLight Biosciences

Develops RNA-based agricultural pest control

Overview

GreenLight Biosciences develops RNA-based solutions for agriculture and health, aiming to improve crop productivity and protect crops from pests while promoting environmental sustainability. Its products work by using RNA to silence or disrupt specific genes in pests or target organisms, delivered through formulations that can be sprayed or applied to fields, creating a targeted pest-management approach. The company differentiates itself by focusing on RNA technology as a platform to deliver precise, species-specific effects that reduce chemical inputs and support sustainable farming, unlike traditional chemical pesticides. Its goal is to advance RNA technologies to enable sustainable agriculture and healthier outcomes for both crops and people, positioning itself as a leader in bioscience focused on real-world agricultural impact.

About GreenLight Biosciences

Simplify's Rating
Why GreenLight Biosciences is rated
C
Rated B on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Food & Agriculture

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$629.5M

Headquarters

Medford, Massachusetts

Founded

2008

People at GreenLight Biosciences

People at GreenLight Biosciences who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Brazil serves as GreenLight's strategic launchpad and future regional export hub for high-value crops like grapes, tomatoes, and coffee[2].
  • The company secured €35 million from the European Investment Bank to scale RNA-based biocontrol research and production in Spain, strengthening EU capacity[2].
  • GreenLight plans to launch three new RNA-based products in 2026–2027 targeting powdery mildew, expanding its fungicide portfolio beyond current offerings[5].

What critics are saying

  • Bayer launches RNA-based Colorado potato beetle product 'BeetStop' in August 2026 at 30% lower price, threatening Calantha's U.S. market share and sales[1].
  • Brazilian regulator MAPA may reverse Act No. 62 in Q3 2026, removing RNAi bio-inputs from priority review and blocking Oifirax registration, canceling the $25M expansion plan[2].
  • Fall Line Capital could initiate bankruptcy liquidation in March 2027 due to $85M debt default, leading to asset seizure of the cell-free RNA platform and R&D termination[1].

What makes GreenLight Biosciences unique

  • GreenLight pioneered RNA-based fungicide Oifirax, the world's first registered RNAi crop protection product for powdery mildew in Brazil[1].
  • Its proprietary cell-free manufacturing platform enables rapid, cost-effective double-stranded RNA production, overcoming historical cost barriers for agricultural RNAi applications[2].
  • GreenLight's RNAi products are non-GMO, degrade completely within days, and have zero impact on pollinators, unlike traditional chemical pesticides[3].

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$629.5M

Above

Industry Average

Funded Over

12 Rounds

Growth Equity VC funding comparison data is currently unavailable. We're working to provide this information soon!
Growth Equity VC Funding Comparison
Coming Soon

Benefits

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Newfold Digital
Oct 16th, 2025
The Week in AgriFoodTech: Wild Bioscience raises $60m, Starship lands $50m, new EU agrifood grants

The week in agrifoodtech: wild Bioscience raises $60m, starship lands $50m, new EU agrifood grants. Plus: crop protection platform Ascribe Bioscience raises $12 million.

AgriBusiness Global
Sep 26th, 2025
GreenLight Biosciences Launches Norroa, the First RNA-Based Treatment for Varroa Mites

GreenLight Biosciences launches Norroa, the first rna-based treatment for varroa mites.

UNI NETWORK GROUP
Sep 25th, 2025
GreenLight Biosciences Launches Norroa: First RNA-Based Treatment for Varroa Mites

GreenLight Biosciences has announced the EPA registration of Norroa(TM), the world's first RNA-based treatment designed to combat varroa mites - the leading threat to honey bee colonies.

Rochester Business Journal
May 13th, 2025
GreenLight Biosciences expands manufacturing operations in Rochester

GreenLight Biosciences expands manufacturing operations in Rochester.

GrowinAgri
Mar 31st, 2025
Greenlight Biosciences Secures $25M in Series C Funding to Drive Sustainable Agriculture

Greenlight Biosciences recently closed its Series C Funding round $25 Million from just Climate and other investors.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for GreenLight Biosciences right now.

Find jobs on Simplify and start your career today

We update GreenLight Biosciences's jobs every few hours, so check again soon! Browse all jobs →